Early AI Winners in Healthcare Are Emerging—Here’s What They’re Doing Differently
Issued on behalf of Avant Technologies Inc.
VANCOUVER – Baystreet.ca News Commentary – Doctors are quite bullish on the newfound abilities coming from artificial intelligence (AI) in healthcare, according to a new report from Philip, however patients aren’t so sure yet. As per the survey of 63% of 200 healthcare professionals and only 48% of over 1,000 patients in the USA believe AI could be helpful for improving health outcomes. Researchers are currently studying what are the critical activities for successful implementation and adoption of AI in healthcare, while tech and biotech companies are already making innovations in the space, with recent developments coming from Avant Technologies, Inc. (OTCQB: AVAI), Amazon.com, Inc. (NASDAQ: AMZN), Doximity, Inc. (NYSE: DOCS), GE HealthCare Technologies Inc. (NASDAQ: GEHC), and Weave Communications, Inc. (NYSE: WEAV).
Industry analysts at MarketsandMarkets project that the AI in healthcare market will expand at a compound annual growth rate of 38.6%, reaching over $110 billion by 2030. Recently private company Pathos AI secured $365 million in Series D financing to advance cancer drug development through AI.
Avant Technologies, Inc. (OTCQB: AVAI), in partnership with Ainnova Tech, is positioning its Vision AI platform at the forefront of predictive healthcare. The company is in advanced discussions to acquire or exclusively license a patented early disease detection technology that could significantly enhance its diagnostic capabilities. If finalized, the deal would allow Vision AI to generate clinical insights even in the absence of a complete patient dataset—unlocking earlier intervention opportunities and supporting a more proactive model of care.
“Our purpose is to create the future of early disease detection in an accessible way, so that patients can get a preventive check-up anywhere, at a low cost, and easily,” said Vinicio Vargas, CEO at Ainnova and member of the Board of Directors of the joint venture company, Ai-nova Acquisition Corp. (AAC), said of AAC’s aim to continue to add to its portfolio. “We want to prevent patients with risk factors from developing other diseases that could have been avoided before they became a real problem. To this end, we are seeking to integrate new technologies into our portfolio within a single platform, both through our R&D efforts and through potential exclusive licenses or acquisitions.”
The potential acquisition aligns with Avant and Ainnova’s shared mission to deliver scalable, preventive health tools that merge retinal imaging, vital sign monitoring, and machine learning into one streamlined platform. Vision AI is already positioned as a next-generation diagnostic engine for chronic conditions like diabetes, cardiovascular disease, and kidney dysfunction. Now, the joint venture is pushing further—evaluating breakthrough technologies that could detect emerging health issues at a pre-symptomatic stage.
Recent platform updates saw four proprietary algorithms—trained on over 2.3 million real-world clinical cases—fully integrated into Vision AI. The addition of new IP from this proposed deal would mark a significant leap forward, enabling predictive models to extract meaningful signals from even limited patient data.
Avant and Ainnova view this initiative as part of a broader strategy to consolidate breakthrough tools that make early disease detection more scalable, mobile, and applicable across diverse healthcare settings. While a final agreement has yet to be announced, the companies have stated they will keep shareholders informed as developments progress.
In parallel, Avant has entered formal discussions to acquire Ainnova outright—building on their existing alignment under the Ai-nova Acquisition Corp. (AAC) structure. The timing is deliberate, coming just ahead of a planned FDA pre-submission meeting this July. A completed merger would unify operations, reduce internal complexity, and bolster the joint venture’s regulatory readiness as it prepares for potential U.S. market entry.
“We believe bringing the two companies together will offer tremendous value for shareholders,” said Vargas. “It will simplify the process of advancing our technology to market, and it will deliver value to our customers and partners as we promote our technology portfolio globally.”
At the center of this initiative is Vision AI—a non-invasive screening platform that integrates retinal imaging, vital sign monitoring, and machine-learning models to flag early indicators of chronic disease. The system targets conditions such as diabetic retinopathy, cardiovascular issues, kidney and liver disorders, and type 2 diabetes. Operated under the AAC structure, the joint venture holds global rights to Vision AI, which has demonstrated over 90% sensitivity in early detection based on research cited by the NIH.
"This milestone reflects our two-tiered strategy, rapid deployment in low-regulation markets where Vision AI operates as a screening tool, and simultaneous progress toward FDA clearance for the U.S. market,” said Vargas. “Entering the U.S. will unlock significant commercial potential, and early engagement with regulators ensures we do so with speed, credibility, and a validated product."
While many AI healthcare platforms remain stuck in pilot stages, Avant’s Vision AI is already live across multiple Latin American markets—including Chile, Mexico, and Brazil—where it’s actively being used in clinical settings. These real-world deployments are generating essential data on safety and efficacy, while also providing user feedback that guides ongoing system improvements.
To broaden its diagnostic reach, the Ai-nova joint venture recently integrated four additional algorithms into the platform. Each was trained on a dataset of more than 2.3 million clinical records, enhancing Vision AI’s precision across a wider spectrum of chronic diseases. With active momentum abroad and U.S. regulatory discussions now underway, Avant’s trajectory appears to be moving from early validation toward broader market penetration.
CONTINUED… Read this and more news for Avant Technologies Inc. https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
Amazon Web Services (AWS), the cloud division of Amazon.com, Inc. (NASDAQ: AMZN), has launched a powerful new open-source toolkit to accelerate agentic AI adoption across the life sciences sector. Built on Amazon Bedrock, the platform includes specialized AI agents for tasks like biomarker discovery, clinical trial design, and competitive intelligence—streamlining workflows that once took days or weeks.
“We introduced the open-source Healthcare and Life Sciences Agentic AI toolkit, which includes starter agents built on Amazon Bedrock,” said Brian Loyal, Worldwide Tech Leader for Healthcare and Life Sciences at Amazon Web Services. “These agents demonstrate real-world capabilities like biomarker discovery, clinical protocol development, and competitive intelligence analysis.”
Early users are leveraging the system to deploy secure, multi-agent solutions across research, development, and commercialization.
Doximity, Inc. (NYSE: DOCS) closed out fiscal 2025 with $138.3 million in Q4 revenue and $570.4 million for the year—marking a 20% year-over-year increase, alongside record profitability. Full-year free cash flow rose 50% to $266.7 million, and adjusted EBITDA reached $313.8 million, reflecting a 36% gain. With strong user engagement across its AI tools and medical workflow suite, the company projects up to $631 million in fiscal 2026 revenue.
"We closed out fiscal 2025 on a high note, with record engagement, strong profits, and 20% annual revenue growth," said Jeff Tangney, Co-Founder and CEO of Doximity Inc. "Our newsfeed, workflow, and AI tools all hit fresh highs in Q4, helping doctors save time and provide the best care for their patients."
Doximity also issued Q1 guidance of $139–140 million in revenue and up to $72 million in adjusted EBITDA.
GE HealthCare Technologies Inc. (NASDAQ: GEHC) has unveiled CleaRecon DL, a deep learning-powered enhancement for cone-beam computed tomography (CBCT) imaging, now available in the U.S. and EU. Integrated into the Allia platform, the system improves image clarity by reducing artifacts and streamlining workflows for interventional radiologists.
"The introduction of CleaRecon DL represents a leap forward in the interventional suite and for the advancement of CBCT," said Arnaud Marie, General Manager, Interventional Solutions at GE HealthCare. ”By improving image quality and reducing artifacts, this technology can empower clinicians to perform procedures with greater precision and confidence. This solution builds on our portfolio of tools aimed at improving the user experience and workflow efficiency, enabling clinicians to deliver more accurate and effective interventions for enhanced patient outcomes."
The company is showcasing this innovation at the 2025 GEST Annual Meeting as part of its continued push to elevate precision imaging and clinical efficiency.
Weave Communications, Inc. (NYSE: WEAV) recently completed its acquisition of TrueLark, an AI-powered virtual front desk platform, in a $35 million deal aimed at transforming patient engagement and administrative automation in SMB healthcare.
"TrueLark represents more than a new product, the acquisition positions Weave at the forefront of agentic AI in SMB healthcare," said Brett White, CEO of Weave. "The acquisition will deliver a virtual assistant that helps practices fill more appointments, improve responsiveness, and drive stronger patient engagement, all without increasing headcount."
The acquisition expands Weave’s AI footprint with always-on, autonomous assistants capable of booking appointments, handling after-hours communications, and reducing front-office burden. TrueLark’s conversational AI is already gaining traction in multi-location practices, positioning Weave to accelerate adoption of intelligent automation across a $32 billion global market opportunity.
CONTACT:
Baystreet.ca
(250) 661-3391
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Baystreet.ca is a wholly-owned subsidiary of Baystreet.ca Media Corp. (“BAY”) BAY has been not been paid a fee for Avant Technologies Inc. advertising and/or digital media, but the owner(s) of BAY also own Market IQ Media Group, Inc., which has been paid a fee from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of BAY own shares of Avant Technologies Inc. which were purchased in the open market. BAY and all of it’s respective employees, owners and affiliates reserve the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by BAY has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
